Publication | Closed Access

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Molecular PharmacologyIntravenous Ly2090314Glycogen SynthaseFirst-in-human PhaseMedicinePharmacotherapyDrug DevelopmentPharmacologyRadiation OncologyPharmacokineticsDrug Discovery